RARECAUTIOUS

Gross Margin

77.9%

Higher than 76% of Healthcare sector peers

Updated 1078h ago

Sector Performance

76th percentile

RARE

77.9%

Sector Median

68.9%

Sector Avg

-20.2%

📊

Deep Analysis

Ultragenyx Pharmaceutical Inc. (RARE) has a Gross Margin of 77.9% as of May 2026.

This places RARE in the 76th percentile of the Healthcare sector, which has a median Gross Margin of 68.9% and a sector average of -20.2%. RARE's Gross Margin is 13.1% above the sector median. In context: Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

Frequently Asked Questions

What does the Gross Margin tell investors about RARE?

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.

How is the Gross Margin calculated?

Gross Margin is calculated as: Gross Profit / Revenue.

How does RARE's Gross Margin compare to its sector?

RARE's Gross Margin of 77.9% compares to a Healthcare sector median of 68.9%, placing it in the 76th percentile.

Who are RARE's closest peers by Gross Margin?

The closest Healthcare peers by Gross Margin include: AMGN (68.2%), TDOC (67.8%), TECH (66.9%), NTRA (64.8%), RMD (62.2%).

The Formula

Gross Profit / Revenue

Why It Matters

Gross margin reveals pricing power and cost structure. Software companies often sustain 70–80%; manufacturers typically 30–50%. Expansion is a bullish signal.